Asia Pacific Home Infusion Therapy Market Size, Share & Trends Analysis Report By Type (Products, Services), By Product (Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors), By Application (Anti-Infective, Endocrinology, Hydration Therapy, Chemotherapy, Enteral Nutrition, Parenteral Nutrition, Specialty Pharmaceuticals) and By Country (China, Korea, Japan, India, Australia, Taiwan, South East Asia, Rest of Asia-Pacific) Forecasts, 2026-2034

Market Overview

The Asia Pacific home infusion therapy market size was valued at USD 9.46 billion in 2025 and is estimated to grow from USD 10.33 billion in 2026 to reach USD 20.89 billion by 2034, growing at a CAGR of 9.2% during the forecast period 2026–2034.

An alternative to taking medication by mouth is infusion therapy, which is how the term is defined. The infusion process involves monitoring the administration of medication with the assistance of a sterile catheter inserted into a vein.

Home infusion therapy refers to giving an individual medication or biologicals through an intravenous or subcutaneous route while they live in their residence. The medication (such as antivirals or immune globulin, for example), the necessary piece of medical equipment (such as a pump), and the necessary medical supplies are required to carry out home infusion (for example, tubing and catheters). In a similar vein, nursing services are required to educate and train both the patient and the caregivers administering the infusion medications in the patient's home. Home infusion treatment frequently requires a significant contribution from visiting nurses. Typically, nurses will instruct the patient or the caregiver on how to self-administer the medication, educate the patient about the potential adverse effects of the treatment and the aims of therapy, and visit the patient occasionally to evaluate the infusion site and change the dressing. In most cases, the procedure of home infusion needs coordination among several different parties. These parties can include patients, physicians, hospital discharge planners, health plans, home infusion pharmacies, and, if necessary, home health organisations.

Market Dynamics

Market Drivers

Increasing Elderly Population

The elderly population is increasing. As the senior population grows, so will many medical conditions requiring long-term care. The growing preference of this age group for in-home healthcare services is expected to significantly increase demand for home infusion therapy products and services during the forecast period.

Chronic diseases that necessitate long-term care constitute a significant risk factor for ageing. Alzheimer's disease, dementia, diabetes, and other orthopaedic illnesses that impair movement are serious diseases associated with ageing (the risk of Alzheimer's disease approaches 50% for people aged 85 and up). People prefer home care as a result of the factor mentioned above. For example, nearly 70% of home healthcare patients are 65 or older.

Furthermore, the growing senior population in Asian countries and the presence of vast untapped opportunities in developing countries such as Japan and China are expected to drive market growth during the forecast period. For example, it is estimated that by 2050, around 79 per cent of the global population aged 60 and up will be living in developing countries.

A Cost-Effective Alternate for the Hospital Stay

Home infusion is considered a more cost-effective alternative to an extended hospital stay or nursing home placement for patients with chronic diseases. Medication administration or infusion at home promotes faster recovery, a better experience, fewer complications, and lower costs. Home infusion therapy allows many patients to resume their daily activities, significantly improving their quality of life.

Market Restraints

The Presence of A Complex Reimbursement Framework as Well as Reimbursement Cuts

One of the major factors driving the market growth is Medicare reimbursement for home healthcare providers and patients. Recent reimbursement cuts and rebasing of home health funding, on the other hand, are expected to hinder market growth during the forecast period. Medicare proposed cutting home health funding by 3.5 per cent per year from 2014 to 2017 in its draught of the Home Health Prospective Payment System (HPPS) rule for 2014. It is expected to significantly impact home health funding and limit patients' and senior citizens' ability to access clinically advanced and cost-effective home-based care. Rebasing has resulted in lower average margins, which have fallen from 8.6 per cent in 2014 to 5.0 per cent in 2017. Furthermore, the elimination of 170 ICD-9 codes from home healthcare reimbursement policies is expected to limit market growth during the forecast period.

Asia Pacific Home Infusion Therapy Market Segmentation Analysis

By Type

The Asia Pacific Home Infusion Therapy Market is segmented into Products and Services. Products include medical devices and consumables used to administer medications, fluids, nutrients, and other therapies in home-based settings, while services include nursing support, patient education, therapy management, monitoring, and other clinical and administrative services required for safe home infusion treatment. The growing shift toward home-based care, increasing prevalence of chronic diseases, rising healthcare expenditure, and the need to reduce hospital stays are supporting demand for both products and services. Products remain essential to the delivery of infusion therapy, while services are becoming increasingly important as healthcare providers focus on ensuring treatment adherence, patient safety, and effective management outside hospital settings.

Increasing adoption of home healthcare, improvements in infusion technologies, expansion of healthcare infrastructure, and growing awareness of the benefits of receiving treatment at home are creating opportunities across the two type segments. Product demand is supported by the need for reliable infusion pumps, administration sets, cannulas, connectors, and other consumables, while service demand is strengthened by the requirement for trained healthcare professionals and continuous patient support. The growing elderly population and rising incidence of conditions requiring long-term intravenous or nutritional therapy are expected to further encourage the transition from hospital-based treatment to home infusion programs across Asia Pacific.

Request Customizationto receive a tailored report.

By Product

The Asia Pacific Home Infusion Therapy Market is segmented into Infusion Pumps, Intravenous Sets, IV Cannulas, and Needleless Connectors. Infusion pumps provide controlled delivery of medications, fluids, and nutrients and are particularly important when precise administration rates are required. Intravenous sets facilitate the connection and delivery of infusion solutions, while IV cannulas provide vascular access for administering therapies. Needleless connectors support safer and more convenient connections between infusion components and can help reduce the risks associated with repeated needle use. The selection of these products depends on therapy type, treatment duration, patient condition, infusion volume, and healthcare-provider requirements.

Growing demand for home-based treatment, increasing prevalence of chronic diseases, rising adoption of portable and technologically advanced infusion devices, and the expansion of home healthcare services are supporting product demand. Infusion pumps are gaining importance because of their ability to provide controlled and programmable therapy, while intravenous sets, IV cannulas, and needleless connectors benefit from the increasing number of patients receiving repeated or long-term infusion treatment. Improvements in product design, increasing focus on patient safety, and the need to simplify home-based administration are expected to encourage wider adoption of infusion therapy products across Asia Pacific.

By Application

The Asia Pacific Home Infusion Therapy Market is segmented into Anti-Infective, Endocrinology, Hydration Therapy, Chemotherapy, Enteral Nutrition, Parenteral Nutrition, and Specialty Pharmaceuticals. Anti-infective therapy is commonly administered through home infusion for patients requiring prolonged treatment, while endocrinology applications include therapies requiring regular medication administration and monitoring. Hydration therapy provides fluids and electrolytes to patients who cannot maintain adequate hydration, whereas chemotherapy can be delivered in selected home-care settings under appropriate clinical supervision. Enteral and parenteral nutrition support patients who cannot obtain adequate nutrition through normal oral intake, while specialty pharmaceuticals include complex or high-value therapies requiring specialized administration and monitoring.

Rising prevalence of chronic and infectious diseases, an aging population, increasing demand for convenient treatment options, and growing efforts to reduce hospital utilization are supporting home infusion applications across the region. Hydration therapy, anti-infective treatment, and nutritional therapies are benefiting from the expanding use of home-based care, while specialty pharmaceuticals and chemotherapy are creating opportunities as healthcare systems develop more sophisticated home treatment programs. Increasing patient preference for receiving appropriate therapies in familiar home environments, improvements in remote monitoring, and greater availability of trained home healthcare professionals are expected to strengthen adoption across these application categories.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The market is divided into India, Japan, China, Australia, South Korea, Malaysia, Indonesia, Singapore, Philippines & Thailand, based on country. The Asia-Pacific home infusion therapy market is expected to proliferate due to advanced healthcare infrastructure and increased patient awareness of home care benefits. Due to an increasing number of government steps to improve the country's overall healthcare system, Japan held the most significant share in the Asia-Pacific in 2021.

In Japan, for example, the government launched a home healthcare programme in 2018 to make home care solutions more viable. Furthermore, reimbursement for home-based parenteral, enteral nutrition, and pain management therapy has increased. As a result, the Japanese home infusion therapy market is expected to expand during the forecast period.

List of Key and Emerging Players in Asia Pacific Home Infusion Therapy Market

• Braun Melsungen AG
• JMS Co. Ltd.
• Baxter
• Smiths’ Medical
• Caesarea Medical Electronics
• Fresenius Kabi
• Eli Lilly and Company
• CareFusion Corporation
• Terumo Corporation
• ICU Medical, Inc.